Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation

Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. However, the majority of patients achieving remission with TKI still have molecular evidences of disease persistence. Various mech...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bedel, Aurélie, Pasquet, Jean- Max, Lippert, Éric, Taillepierre, Miguel, Lagarde, Valérie, Dabernat, Sandrine, Dubus, Pierre, Charaf, Lucie, Beliveau, François, de Verneuil, Hubert, Richard, Emmanuel, Mahon, François-Xavier, Moreau-Gaudry, François
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751925/
https://ncbi.nlm.nih.gov/pubmed/24058405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0071596
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller